KBC Group
COGT icon

KBC Group’s Cogent Biosciences COGT Stock Holding History

KBC Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$126K Hold
3,946
– – ﹤0.01% 1256
2026
Q2 		$153K Buy
3,946
+1,272
+48% +$44.5K ﹤0.01% 1162
2026
Q1 		$103K Buy
+2,674
New +$98.7K ﹤0.01% 1301

Other funds holding COGT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Mutual of America Capital Management
Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Harbor Investment Advisory
Harbor Investment Advisory Lutherville, Maryland $1.47B AUM 24.2% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Loring Wolcott & Coolidge Fiduciary Advisors
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.8B AUM 9.05% 1-Year Est. Return

KBC Group's COGT Position: Q3 2026 in Review

KBC Group held its Cogent Biosciences (COGT) position steady in Q3 2026 at 3,946 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #1256.

KBC Group first reported a position in COGT in Q1 2026 and has held it in 3 quarters since. The position peaked at $153K in Q2 2026. 29 funds tracked by Wall St. Rank hold COGT as of Q3 2026.

  • KBC Group held 3,946 shares of Cogent Biosciences worth $126K as of Q3 2026.
  • KBC Group left its Cogent Biosciences share count unchanged in Q3 2026.
  • Cogent Biosciences made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1256 holding.
  • KBC Group first reported a position in Cogent Biosciences in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Cogent Biosciences position peaked at $153K in Q2 2026.
  • 29 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.